Novartis Buys Exclusive Rights to Anti-Smoking 'Vaccine'

Novartis AG said Wednesday it will pay Cytos Biotechnology AG up to 600 million Swiss francs (US$500 million; €366 million) for the exclusive right to develop, produce and market an experimental drug it hopes will help cure smokers of their habit.
International Herald Tribune